Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
A. K. Weiner, A. Palmer, M. F. Moll, G. Lindberg, K. Reidy, S. J. Diskin, C. L. Mackall, J. M. Maris, P. J. Sullivan
This paper describes a collaborative model between young investigators and cancer advocates to enhance pediatric cancer research through improved communication and team science.
bioRxiv · Dec 3, 2023Scientific Communication & Education
S. A. Yamada-Hunter, J. Theruvath, B. J. McIntosh, K. A. Freitas, M. T. Radosevich, A. Leruste, S. Dhingra, N. Martinez-Velez, P. Xu, A. Delaidelli, M. H. Desai, Z. Good, L. Labanieh, C. W. Mount, Y. Chen, , C. L. Mackall
This paper engineers a CD47 variant to protect T cells from macrophage clearance, enhancing antitumor efficacy by combining T cell and macrophage activation.
bioRxiv · Jun 20, 2023 · PreprintBioengineering
D. D. Klysz, C. Fowler, M. Malipatlolla, L. Stuani, K. A. Freitas, S. Meier, B. Daniel, K. Sandor, P. Xu, J. Huang, L. Labanieh, A. Leruste, M. Bashti, V. Keerthi, J. Mata-Alcazar, , C. L. Mackall
This study shows that inosine enhances CAR T cell stemness and function by modulating metabolism and epigenetics, leading to improved anti-tumor potency.
bioRxiv · Apr 21, 2023Immunology
K. A. Freitas, J. A. Belk, E. Sotillo, B. Daniel, K. Sandor, D. Klysz, V. T. Duong, K. A. Burdsall, P. Xu, M. Malipatlolla, M. G. Donovan, E. W. Weber, R. G. Majzner, H. Y. Chang, J. M. Espinosa, , C. L. Mackall
This study identifies the Mediator kinase module as a regulator of T cell differentiation and shows that its inhibition enhances effector T cell potency.
bioRxiv · Sep 2, 2022 · PreprintImmunology
A. K. Grosskopf, L. Labanieh, D. D. Klysz, G. Roth, P. Xu, O. Adebowale, E. C. G. C. Gale, C. K. Jons, J. H. Klich, J. Yan, C. L. Maikawa, S. Correa, B. S. Ou, A. I. d'Aquino, J. R. Cochran, , E. Appel
This paper develops an injectable hydrogel to co-deliver CAR-T cells and cytokines, enhancing solid tumor treatment in mice by creating a transient inflammatory niche.
bioRxiv · Dec 20, 2021Bioengineering
J. Theruvath, M. Menard, B. A. Smith, M. H. Linde, G. Coles, W. Wu, L. Kiru, A. Delaidelli, J. L. Silberstein, A. Banuelos, S. Dhingra, E. Sotillo, S. Heitzeneder, A. Tousley, J. Lattin, , R. G. Majzner
This study shows that combining anti-GD2 and anti-CD47 antibodies enhances anti-tumor responses by recruiting macrophages and disrupting the GD2:Siglec-7 interaction in GD2+ cancers.
bioRxiv · Mar 19, 2021 · PreprintImmunology
F. Simonetta, J. K. Lohmeyer, T. Hirai, K. Maas-Bauer, M. Alvarez, A. S. Wenokur, J. Baker, A. Aalipour, X. Ji, S. Haile, C. L. Mackall, R. S. Negrin
This study shows allogeneic CAR-iNKT cells effectively combat tumors in mice by directly attacking cancer cells and boosting host CD8 T cell responses, even across major MHC barriers.
bioRxiv · Feb 3, 2021Immunology
C. Lamarche, G. Novakovsky, C. N. Qi, E. W. Weber, C. L. Mackall, M. K. Levings
This study shows that human regulatory T cells (Tregs) can become exhausted through repetitive stimulation or tonic-signaling CARs, reducing their suppressive function in vivo.
bioRxiv · Jun 27, 2020 · PreprintImmunology
E. W. Weber, R. C. Lynn, K. R. Parker, H. Anbunathan, J. Lattin, E. Sotillo, Z. Good, M. Malipatlolla, P. Xu, P. Vandris, R. G. Majzner, Y. Qi, L.-C. Chen, A. J. Gentles, T. J. Wandless, , C. L. Mackall
This study shows that temporarily stopping CAR-T cell signaling can reverse exhaustion and improve their anti-tumor function through transcriptional and epigenetic changes.
bioRxiv · Jan 26, 2020 · PreprintImmunology
R. C. Lynn, E. W. Weber, D. Gennert, E. Sotillo, P. Xu, Z. Good, H. Anbunathan, R. Jones, V. Tieu, J. Granja, C. DeBourcy, R. Majzner, A. Satpathy, S. R. Quake, H. Chang, C. L. Mackall
This study shows that overexpressing c-Jun in CAR-T cells reduces exhaustion and improves antitumor activity in vivo.
bioRxiv · May 29, 2019 · PreprintImmunology